Shahrokh Javaheri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shahrokh Javaheri has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Laura Wexler
Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH; Department of Veterans Affairs Medical Center, Cincinnati, OH
3 shared publicationsEugene Chung
Sleepcare Diagnostics, and the Department of Cardiology, Christ Hospital, Cincinnati, USA
2 shared publicationsJason Smith
Sleepcare Diagnostics, and the Department of Cardiology, Christ Hospital, Cincinnati, USA
2 shared publicationsRakesh Shukla
Departments of Medicine and Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH
2 shared publicationsAthar Malik
Sleepcare Diagnostics, University of Cincinnati, Mason, USA
1 shared publicationE. Ben Caref
Medtelligence, LLC, Philadelphia, PA
1 shared publication
Latest Publications
- 1 January 2013
- Published by Wiley
- Vol. 3 (1) , 141-163
Central Sleep Apnea
Neurophysiologically, central apnea is due to a temporary failure in the pontomedullary pacemaker generating breathing rhythm. As a polysomnographic finding, central apneas occur in many pathophysiological conditions. Depending on the cause or mechanism, central apneas may not be clinically significant, for example, those that occur normally at sleep onset. In contrast, central apneas occur in a number of disorders and result in pathophysiological consequences. Central apneas occur commonly in high‐altitude sojourn, disrupt sleep, and cause desaturation. Central sleep apnea also occurs in number of disorders across all age groups and both genders. Common causes of central sleep apnea in adults are congestive heart failure and chronic use of opioids to treat pain. Under such circumstances, diagnosis and treatment of central sleep apnea may improve quality of life, morbidity, and perhaps mortality. The mechanisms of central sleep apnea have been best studied in congestive heart failure and hypoxic conditions when there is increased CO2sensitivity below eupnea resulting in lowering eupneic PCO2below apneic threshold causing cessation of breathing until the PCO2rises above the apneic threshold when breathing resumes. In many other disorders, the mechanism of central sleep apnea (CSA) remains to be investigated. © 2013 American Physiological Society.Compr Physiol3:141‐163, 2013.
- 1 January 2013
- Published by Wiley
- Vol. 3 (1) , 141-163
Central Sleep Apnea
Neurophysiologically, central apnea is due to a temporary failure in the pontomedullary pacemaker generating breathing rhythm. As a polysomnographic finding, central apneas occur in many pathophysiological conditions. Depending on the cause or mechanism, central apneas may not be clinically significant, for example, those that occur normally at sleep onset. In contrast, central apneas occur in a number of disorders and result in pathophysiological consequences. Central apneas occur commonly in high‐altitude sojourn, disrupt sleep, and cause desaturation. Central sleep apnea also occurs in number of disorders across all age groups and both genders. Common causes of central sleep apnea in adults are congestive heart failure and chronic use of opioids to treat pain. Under such circumstances, diagnosis and treatment of central sleep apnea may improve quality of life, morbidity, and perhaps mortality. The mechanisms of central sleep apnea have been best studied in congestive heart failure and hypoxic conditions when there is increased CO2sensitivity below eupnea resulting in lowering eupneic PCO2below apneic threshold causing cessation of breathing until the PCO2rises above the apneic threshold when breathing resumes. In many other disorders, the mechanism of central sleep apnea (CSA) remains to be investigated. © 2013 American Physiological Society.Compr Physiol3:141‐163, 2013.
- 1 December 2011
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 34 (12) , 1693-1698
The Performance of Two Automatic Servo-Ventilation Devices in the Treatment of Central Sleep Apnea
S and full research articles published in SLEEP, the official journal of the APSS. Sleep and sleep disorder scientific findings.
- 1 December 2011
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 34 (12) , 1693-1698
The Performance of Two Automatic Servo-Ventilation Devices in the Treatment of Central Sleep Apnea
S and full research articles published in SLEEP, the official journal of the APSS. Sleep and sleep disorder scientific findings.
- 15 August 2011
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 7 (4) , 399-400
Resolution of Papilledema Associated with OSA Treatment
Obstructive sleep apnea (OSA) is a common disorder and is associated with brain functional and morphological alterations. The association between OSA and papilledema, however, is not well known. We describe a 53-year-old morbidly obese female who presented with impaired vision due to bilateral papilledema. Polysomnography revealed severe OSA. She was treated with continuous positive airway pressure, and within a few weeks her papilledema and vision improved. This case report is consistent with association of OSA with papilledema but does not prove causality.
- 15 August 2011
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 7 (4) , 399-400
Resolution of Papilledema Associated with OSA Treatment
Obstructive sleep apnea (OSA) is a common disorder and is associated with brain functional and morphological alterations. The association between OSA and papilledema, however, is not well known. We describe a 53-year-old morbidly obese female who presented with impaired vision due to bilateral papilledema. Polysomnography revealed severe OSA. She was treated with continuous positive airway pressure, and within a few weeks her papilledema and vision improved. This case report is consistent with association of OSA with papilledema but does not prove causality.
- 15 February 2011
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 183 (4) , 539-546
Sleep Apnea Testing and Outcomes in a Large Cohort of Medicare Beneficiaries with Newly Diagnosed Heart Failure
Rationale: Previous studies have demonstrated a high prevalence of sleep apnea (SA) in patients with chronic heart failure (HF), which is associated with higher rates of morbidity, mortality, and health care use. Objectives: To investigate the reported incidence, treatment, outcomes, and economic cost of SA in new-onset HF in a large U.S. database. Methods: This retrospective cohort study used the 2003 to 2005 Medicare Standard Analytical Files and included subjects with newly diagnosed HF from the first quarter of 2004, without prior diagnosis of SA, stratified by testing, diagnosis, and treatment status. Measurements and Main Results: Among a study population of 30,719 incident subjects with HF, only 1,263 (4%) were clinically suspected to have SA. Of these, 553 (2% of the total cohort) received SA testing, and 545 received treatment. After adjustment for age, sex, and comorbidities, subjects with HF who were tested, diagnosed, and treated for SA had a better 2-year survival rate compared with subjects with HF who were not tested (hazard ratio, 0.33 [95% confidence interval, 0.21–0.51], P < 0.0001). Similarly, among subjects who were tested and diagnosed, those who were treated had a better 2-year survival rate than those who were not treated (hazard ratio, 0.49 [95% confidence interval, 0.29–0.84], P = 0.009). Conclusions: In Medicare beneficiaries with HF, comorbid SA is most often not tested and consequently subjects are underdiagnosed and not treated. Meanwhile, in the few subjects in whom a diagnosis of SA is established and treatment is executed, survival improves significantly. These results support the importance of SA testing and treatment for patients newly diagnosed with HF.
- 15 February 2011
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 183 (4) , 539-546
Sleep Apnea Testing and Outcomes in a Large Cohort of Medicare Beneficiaries with Newly Diagnosed Heart Failure
Rationale: Previous studies have demonstrated a high prevalence of sleep apnea (SA) in patients with chronic heart failure (HF), which is associated with higher rates of morbidity, mortality, and health care use. Objectives: To investigate the reported incidence, treatment, outcomes, and economic cost of SA in new-onset HF in a large U.S. database. Methods: This retrospective cohort study used the 2003 to 2005 Medicare Standard Analytical Files and included subjects with newly diagnosed HF from the first quarter of 2004, without prior diagnosis of SA, stratified by testing, diagnosis, and treatment status. Measurements and Main Results: Among a study population of 30,719 incident subjects with HF, only 1,263 (4%) were clinically suspected to have SA. Of these, 553 (2% of the total cohort) received SA testing, and 545 received treatment. After adjustment for age, sex, and comorbidities, subjects with HF who were tested, diagnosed, and treated for SA had a better 2-year survival rate compared with subjects with HF who were not tested (hazard ratio, 0.33 [95% confidence interval, 0.21–0.51], P < 0.0001). Similarly, among subjects who were tested and diagnosed, those who were treated had a better 2-year survival rate than those who were not treated (hazard ratio, 0.49 [95% confidence interval, 0.29–0.84], P = 0.009). Conclusions: In Medicare beneficiaries with HF, comorbid SA is most often not tested and consequently subjects are underdiagnosed and not treated. Meanwhile, in the few subjects in whom a diagnosis of SA is established and treatment is executed, survival improves significantly. These results support the importance of SA testing and treatment for patients newly diagnosed with HF.
- 1 June 2010
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 31 (2) , 235-248
Central Sleep Apnea
- 1 June 2010
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 31 (2) , 235-248
Central Sleep Apnea
- 15 June 2009
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 5 (3) , 205-211
The Prevalence and Natural History of Complex Sleep Apnea
Central sleep apnea (CSA) may occasionally occur in patients with obstructive sleep apnea during titration with a continuous positive airway pressure (CPAP
- 15 June 2009
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 5 (3) , 205-211
The Prevalence and Natural History of Complex Sleep Apnea
Central sleep apnea (CSA) may occasionally occur in patients with obstructive sleep apnea during titration with a continuous positive airway pressure (CPAP
- 1 September 2008
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 10 (5) , 323-335
Sleep dysfunction in heart failure
Chronic congestive heart failure is a highly prevalent and progressive disorder associated with excess morbidity and mortality; it has huge economic impact. Left heart failure may be systolic or may occur as isolated diastolic dysfunction. The diastolic form predominates in older people. Sleep disorders are frequent in both types. Most systematic studies have been performed in patients with systolic heart failure. Prospective studies show the presence of obstructive and central sleep apnea, periodic limb movements, and significant alterations in sleep architecture, characterized by poor efficiency, excess stage 1 and arousals, and lack of deep sleep. Both obstructive sleep apnea and central sleep apnea occur in patients with heart failure and have been shown to be associated with excess mortality. Obstructive sleep apnea is best treated with continuous positive airway pressure (CPAP) devices. Central sleep apnea is also best treated with CPAP, but only about 50% of the patients are considered responders. Survival improves when heart failure patients are effectively treated with CPAP for both central and obstructive sleep apnea. A new positive airway pressure device, a pressure support servo-ventilator, is the next best choice for heart failure patients whose central sleep apnea does not respond to CPAP. Nocturnal oxygen should be used for patients whose central sleep apnea does not respond to positive pressure devices. Both periodic limb movements and insomnia could have adverse hemodynamic consequences for the failing heart. There are no guidelines or long-term studies regarding treatment of these conditions in heart failure. For restless legs syndrome with or without periodic limb movements, pramipexole and ropinirole have been approved. Treatment of insomnia comorbid with heart failure depends on the cause. In the absence of any known cause, a trial of ramelteon is the first choice.
- 1 September 2008
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 10 (5) , 323-335
Sleep dysfunction in heart failure
Chronic congestive heart failure is a highly prevalent and progressive disorder associated with excess morbidity and mortality; it has huge economic impact. Left heart failure may be systolic or may occur as isolated diastolic dysfunction. The diastolic form predominates in older people. Sleep disorders are frequent in both types. Most systematic studies have been performed in patients with systolic heart failure. Prospective studies show the presence of obstructive and central sleep apnea, periodic limb movements, and significant alterations in sleep architecture, characterized by poor efficiency, excess stage 1 and arousals, and lack of deep sleep. Both obstructive sleep apnea and central sleep apnea occur in patients with heart failure and have been shown to be associated with excess mortality. Obstructive sleep apnea is best treated with continuous positive airway pressure (CPAP) devices. Central sleep apnea is also best treated with CPAP, but only about 50% of the patients are considered responders. Survival improves when heart failure patients are effectively treated with CPAP for both central and obstructive sleep apnea. A new positive airway pressure device, a pressure support servo-ventilator, is the next best choice for heart failure patients whose central sleep apnea does not respond to CPAP. Nocturnal oxygen should be used for patients whose central sleep apnea does not respond to positive pressure devices. Both periodic limb movements and insomnia could have adverse hemodynamic consequences for the failing heart. There are no guidelines or long-term studies regarding treatment of these conditions in heart failure. For restless legs syndrome with or without periodic limb movements, pramipexole and ropinirole have been approved. Treatment of insomnia comorbid with heart failure depends on the cause. In the absence of any known cause, a trial of ramelteon is the first choice.
- 15 August 2008
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 4 (4) , 305-310
Adaptive Pressure Support Servoventilation: a Novel Treatment for Sleep Apnea Associated with Use of Opioids
Opioids have become part of contemporary treatment in the management of chronic pain. However, chronic use of opioids has been associated with high prevale
- 15 August 2008
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 4 (4) , 305-310
Adaptive Pressure Support Servoventilation: a Novel Treatment for Sleep Apnea Associated with Use of Opioids
Opioids have become part of contemporary treatment in the management of chronic pain. However, chronic use of opioids has been associated with high prevale